НовостиBenzingaWuhan Hiteck Biological Pharma Enters Into Exclusive License Agreement With NovaBridge’s Visara For HT006.2.2, Investigational Next-Gen Modified rhNGF Eye Drop Wuhan Hiteck Biological Pharma Enters Into Exclusive License Agreement With NovaBridge’s Visara For HT006.2.2, Investigational Next-Gen Modified rhNGF Eye Drop Benzinga 2026.10.13 11:11 (GMT+0) Открыть на Benzinga Другие новости